These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21155183)

  • 1. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data.
    Liu L; Shao X; Gao W; Bai J; Wang R; Huang P; Yin Y; Liu P; Shu Y
    J Thorac Oncol; 2010 Dec; 5(12):1922-32. PubMed ID: 21155183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis.
    Zhan P; Wang J; Lv XJ; Wang Q; Qiu LX; Lin XQ; Yu LK; Song Y
    J Thorac Oncol; 2009 Sep; 4(9):1094-103. PubMed ID: 19687765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
    Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
    J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.
    Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J
    Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer.
    Nakamura H; Saji H; Ogata A; Hosaka M; Hagiwara M; Kawasaki N; Kato H
    Int J Cancer; 2003 Jan; 103(1):61-6. PubMed ID: 12455054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
    Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
    J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting HER2 in the treatment of non-small cell lung cancer.
    Mar N; Vredenburgh JJ; Wasser JS
    Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance analysis between HER2 immunohistochemistry and in situ hybridization in non-small cell lung cancer.
    Ko YS; Kim NY; Pyo JS
    Int J Biol Markers; 2018 Jan; 33(1):49-54. PubMed ID: 28478639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer.
    Kuyama S; Hotta K; Tabata M; Segawa Y; Fujiwara Y; Takigawa N; Kiura K; Ueoka H; Eguchi K; Tanimoto M
    J Thorac Oncol; 2008 May; 3(5):477-82. PubMed ID: 18448999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of HER2 overexpression in non-small cell lung cancer.
    Ugocsai K; Mándoky L; Tiszlavicz L; Molnár J
    Anticancer Res; 2005; 25(4):3061-6. PubMed ID: 16080566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome.
    Onn A; Choe DH; Herbst RS; Correa AM; Munden RF; Truong MT; Vaporciyan AA; Isobe T; Gilcrease MZ; Marom EM
    Radiology; 2005 Oct; 237(1):342-7. PubMed ID: 16183941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.
    Siegfried JM; Lin Y; Diergaarde B; Lin HM; Dacic S; Pennathur A; Weissfeld JL; Romkes M; Nukui T; Stabile LP
    Neoplasia; 2015 Nov; 17(11):817-25. PubMed ID: 26678909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis.
    Wang Y; He L; Cheng Y
    Clin Transl Oncol; 2018 Feb; 20(2):212-220. PubMed ID: 28681313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.
    Mar N; Vredenburgh JJ
    Conn Med; 2015 Oct; 79(9):531-5. PubMed ID: 26630704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
    Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
    Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data.
    Wang Y; Gao W; Xu J; Chen X; Yang Y; Zhu Y; Yin Y; Guo R; Liu P; Shu Y; Liu L
    Biomed Res Int; 2015; 2015():763080. PubMed ID: 26788508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
    Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
    Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis.
    Li X; Zhao H; Gu J; Zheng L
    World J Surg Oncol; 2016 Feb; 14(1):38. PubMed ID: 26897036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
    Im SA; Kim JW; Kim JS; Kim MA; Jordan B; Pickl M; Han SW; Oh DY; Lee HJ; Kim TY; Kim WH; Yang HK; Bang YJ
    Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.